News
Watch
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

New Perspectives on Overactive Bladder: Quality of Life Impact, Medication Persistency, and Treatmen

New Perspectives on Overactive Bladder: Quality of Life Impact, Medication Persistency, and Treatment Costs

ByC. Daniel Mullins, PhD,Leslee L. Subak, MD

July 15th 2005

PARTICIPATING FACULTY

By

July 15th 2005

Persistence With Overactive Bladder Pharmacotherapy in a Medicaid Population

ByFadia T. Shaya, PhD, MPH,Steven Blume, MS,Anna Gu, MA,Teresa Zyczynski, PharmD, MBA, MPH,Zhanna Jumadilova, MD, MBA

July 15th 2005

The Impact of Urinary Incontinence on Quality of Life of the Elderly

ByYu Ko, MS,Swu-Jane Lin, PhD,J. Warren Salmon, PhD,Morgan S. Bron, PharmD, MS

July 15th 2005

Safety and Tolerability of Tolterodine for the Treatment of Overactive Bladder in Adults

ByRichard G. Roberts, MD, JD,Alan D. Garely, MD,Tamara Bavendam, MD

July 15th 2005

Medical Costs After Initiation of Drug Treatment for Overactive Bladder: Effects of Selection Bias on Cost Estimates

ByNicole M. Nitz, PhD,Zhanna Jumadilova, MD, MBA,Theodore Darkow, PharmD,Jennifer R. Frytak, PhD,Tamara Bavendam, MD

July 15th 2005

Economic Impact of Extended-release Tolterodine versus Immediate-and Extended-release Oxybutynin Among Commercially Insured Persons With Overactive Bladder

BySujata Varadharajan, MS,Zhanna Jumadilova, MD, MBA,Prafulla Girase, MS,Daniel A. Ollendorf, MPH

July 15th 2005

Urinary Incontinence in the Nursing Home: Resident Characteristics and Prevalence of Drug Treatment

ByZhanna Jumadilova, MD, MBA,Teresa Zyczynski, PharmD, MBA, MPH,Barbara Paul, MD,Siva Narayanan, MS, MHS

July 15th 2005

Treatment of Overactive Bladder: A Model Comparing Extended-release Formulations of Tolterodine and Oxybutynin

ByEleanor M. Perfetto, PhD,Prasun Subedi, MS,Zhanna Jumadilova, MD, MBA

July 15th 2005

Trending on AJMC

FDA Approves Once-Monthly Subcutaneous Olanzapine for Schizophrenia

MASH Fibrosis, Not Resolution, Predicts Mortality: Zobair Younossi, MD

Bumetanide Nasal Spray Targets Heart Failure Edema Before IV

Timing COVID-19 Protection With VYD2311: Michael Mina, MD, PhD

5 Things to Know About Eye Injury Prevention Month